Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REEM H GHALIB

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1558337782
CMS profile
25140
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$20.65

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $20.65 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $20.65 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REEM H GHALIB

NPI 1558337782 · CMS profile ID 25140

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558337782?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558337782?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558337782?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1558337782?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.6501/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743350033 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21.29 1
PY2020 $20.65 1
PY2021 $46.95 3
PY2024 $1,495.98 14
PY2025 $3,750.18 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,955.82 118
PY2024 Principal investigator $109,074.86 23
PY2023 Principal investigator $199,670.85 30
PY2022 Principal investigator $179,855.97 19
PY2021 Principal investigator $397,738.75 463
PY2020 Principal investigator $682,337.38 146
PY2019 Principal investigator $775,822.80 163

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

146 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,244.88 12/23/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739883777
Principal investigator 1 Novo Nordisk AS $3,204.00 12/22/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411369
Principal investigator 1 Intercept Pharmaceuticals, Inc. $14,767.70 12/16/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739883463
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721312111
Principal investigator 1 Novo Nordisk AS $675.00 11/25/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411367
Principal investigator 1 Gilead Sciences, Inc. $5,058.00 11/18/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742097011
Principal investigator 1 Allergan, Inc. $1,596.00 11/16/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721308319
Principal investigator 1 Gilead Sciences, Inc. $831.00 11/16/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 742083481
Principal investigator 1 Intercept Pharmaceuticals, Inc. $999.18 10/28/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739881905
Principal investigator 1 Novo Nordisk AS $3,648.60 10/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411321
Principal investigator 1 Novo Nordisk AS $13,500.00 10/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411323
Principal investigator 1 Novo Nordisk AS $30,250.00 10/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411325
Principal investigator 1 Novo Nordisk AS $33,000.00 10/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411327
Principal investigator 1 Novo Nordisk AS $2,700.00 10/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411329
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304933
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 10/21/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742083479
Principal investigator 1 Gilead Sciences, Inc. $1,710.00 10/21/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742097009
Principal investigator 1 Allergan, Inc. $684.00 10/19/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303909
Principal investigator 1 Merck Sharp & Dohme Corporation $2,809.28 10/08/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 740827741
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 09/23/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742083477
Principal investigator 1 Gilead Sciences, Inc. $3,178.00 09/23/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742097007
Principal investigator 1 Novo Nordisk AS $2,931.30 09/22/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411319
Principal investigator 1 Allergan, Inc. $3,942.50 09/18/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298697
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,787.76 09/16/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739880707
Principal investigator 1 Novo Nordisk AS $4,491.90 08/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411317
Principal investigator 1 Allergan, Inc. $7,600.00 08/19/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291355
Principal investigator 1 Gilead Sciences, Inc. $1,530.00 08/19/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 742083475
Principal investigator 1 Gilead Sciences, Inc. $1,352.00 08/19/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742097005
Principal investigator 1 Intercept Pharmaceuticals, Inc. $300.00 08/19/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739879861
Principal investigator 1 Intercept Pharmaceuticals, Inc. $420.00 08/12/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739879565
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,536.59 07/29/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739879049
Principal investigator 1 Novo Nordisk AS $6,597.00 07/28/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411097
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 07/22/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742083473
Principal investigator 1 Gilead Sciences, Inc. $363.00 07/22/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742097003
Principal investigator 1 Genentech, Inc. $8,956.94 07/14/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161755
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,978.75 07/08/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739878175
Principal investigator 1 Allergan, Inc. $1,218.85 06/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721281735
Principal investigator 1 Novo Nordisk AS $1,447.20 06/23/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411095
Principal investigator 1 Gilead Sciences, Inc. $842.00 06/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742096999
Principal investigator 1 Gilead Sciences, Inc. $2,315.00 06/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742097001
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,164.97 06/10/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739877691
Principal investigator 1 Genentech, Inc. $12,546.85 06/01/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161705
Principal investigator 1 Genentech, Inc. $4,795.00 06/01/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161713
Principal investigator 1 Genentech, Inc. $18,485.00 06/01/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161725
Principal investigator 1 Genentech, Inc. $2,500.00 06/01/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161735
Principal investigator 1 Genentech, Inc. $2,281.25 06/01/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161745
Principal investigator 1 Novo Nordisk AS $2,256.30 05/28/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410913
Principal investigator 1 Intercept Pharmaceuticals, Inc. $10,000.00 05/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739877045
Principal investigator 1 Allergan, Inc. $2,437.70 05/25/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721276961
Principal investigator 1 Gilead Sciences, Inc. $1,160.00 05/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742096995
Principal investigator 1 Gilead Sciences, Inc. $19,133.00 05/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742096997
Principal investigator 1 Intercept Pharmaceuticals, Inc. $450.00 05/12/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739876447
Principal investigator 1 Intercept Pharmaceuticals, Inc. $325.00 05/12/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739876449
Principal investigator 1 Intercept Pharmaceuticals, Inc. $7,824.47 05/12/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739876453
Principal investigator 1 Intercept Pharmaceuticals, Inc. $22,750.00 05/12/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739876459
Principal investigator 1 Intercept Pharmaceuticals, Inc. $525.00 05/05/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739876167
Principal investigator 1 Intercept Pharmaceuticals, Inc. $500.00 05/05/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739876171
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410945
Principal investigator 1 Gilead Sciences, Inc. $384.00 04/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742096991
Principal investigator 1 Gilead Sciences, Inc. $52,374.00 04/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742096993
Principal investigator 1 Novo Nordisk AS $825.30 04/23/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410909
Principal investigator 1 Novo Nordisk AS $3,500.00 04/23/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410911
Principal investigator 1 Intercept Pharmaceuticals, Inc. $900.90 04/21/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739875791
Principal investigator 1 Allergan, Inc. $3,534.00 04/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271477
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,187.08 04/14/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739875615
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,136.66 04/07/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739875465
Principal investigator 1 Novo Nordisk AS $15,009.30 03/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410899
Principal investigator 1 Novo Nordisk AS $1,562.00 03/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410901
Principal investigator 1 Novo Nordisk AS $2,750.00 03/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410903
Principal investigator 1 Novo Nordisk AS $3,000.00 03/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410905
Principal investigator 1 Novo Nordisk AS $1,800.00 03/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410907
Principal investigator 1 Allergan, Inc. $13,503.30 03/18/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265707
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 03/18/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742083471
Principal investigator 1 Gilead Sciences, Inc. $6,789.00 03/18/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742096989
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262631
Principal investigator 1 Gilead Sciences, Inc. $40,404.00 02/26/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742096987
Principal investigator 1 Gilead Sciences, Inc. $1,725.00 02/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 742083467
Principal investigator 1 Gilead Sciences, Inc. $4,995.00 02/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742083469
Principal investigator 1 Gilead Sciences, Inc. $1,160.00 02/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742096983
Principal investigator 1 Gilead Sciences, Inc. $39,656.00 02/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742096985
Principal investigator 1 Intercept Pharmaceuticals, Inc. $8,052.72 02/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739873441
Principal investigator 1 Intercept Pharmaceuticals, Inc. $574.50 02/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739873445
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,141.30 02/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739873449
Principal investigator 1 Allergan, Inc. $33,473.25 02/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721257905
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,843.80 02/13/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 739872489
Principal investigator 1 Genentech, Inc. $1,473.62 02/03/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 743161695
Principal investigator 1 Allergan, Inc. $115.00 01/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721254655
Principal investigator 1 Novo Nordisk AS $2,025.00 01/28/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410897
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,299.80 01/27/2020 Non-covered Recipient Entity
Texas Clinical Research Institute, Llc
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND COMPENSATED LIVER CIRRHOSIS No dispute reported 06/30/2026 736762605
Principal investigator 1 Gilead Sciences, Inc. $6,870.00 01/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742083465
Principal investigator 1 Gilead Sciences, Inc. $5,545.00 01/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 742096979
Principal investigator 1 Gilead Sciences, Inc. $23,002.00 01/27/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 742096981
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411045
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411047
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411049
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411051
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411053
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411055
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411057
Principal investigator 1 Novo Nordisk AS $60.00 01/24/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411059
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,225.60 01/21/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 739871699
Principal investigator 1 Allergan, Inc. $37,779.60 01/20/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248705
Principal investigator 1 AbbVie Inc. $2,111.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
M13-576 No dispute reported 06/30/2026 721145825
Principal investigator 1 AbbVie Inc. $1,263.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
M13-576 No dispute reported 06/30/2026 721145827
Principal investigator 1 AbbVie Inc. $1,263.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
M13-576 No dispute reported 06/30/2026 721145829
Principal investigator 1 AbbVie Inc. $1,163.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
M13-576 No dispute reported 06/30/2026 721145831
Principal investigator 1 AbbVie Inc. $1,186.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
M13-576 No dispute reported 06/30/2026 721145833
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410963
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410965
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410967
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410969
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410971
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410973
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410975
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410977
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410979
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410981
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410983
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410985
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410987
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410989
Principal investigator 1 Novo Nordisk AS $5.10 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410991
Principal investigator 1 Novo Nordisk AS $25.98 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410993
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410995
Principal investigator 1 Novo Nordisk AS $60.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410997
Principal investigator 1 Novo Nordisk AS $6.50 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742410999
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411001
Principal investigator 1 Novo Nordisk AS $36.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411003
Principal investigator 1 Novo Nordisk AS $22.76 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411011
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411013
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411015
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411017
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411019
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411021
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411023
Principal investigator 1 Novo Nordisk AS $9.80 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411025
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411027
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411029
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411031
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411033
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411035
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411037
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411039
Principal investigator 1 Novo Nordisk AS $9.00 01/17/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 742411041
Principal investigator 1 Celgene Corporation $23,410.92 01/02/2020 Non-covered Recipient Entity
Texas Clinical Research Institute
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis No dispute reported 06/30/2026 736446109
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,505.02 01/01/2020 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO No dispute reported 06/30/2026 721495003